Is the JAK2^V617F mutation detectable in healthy volunteers?MARTINAUD, Christophe; BRISOU, Patrick; MOZZICONACCI, Marie-Joelle et al.American journal of hematology. 2010, Vol 85, Num 4, pp 287-288, issn 0361-8609, 2 p.Article

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneGODFREY, Anna L; CHEN, Edwin; BIJOU, Fontanet et al.Blood. 2012, Vol 120, Num 13, pp 2704-2707, issn 0006-4971, 4 p.Article

Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617FBERKOFSKY-FESSLER, Windy; BUZZAI, Monica; WEIJIA ZHANG et al.Clinical cancer research (Print). 2010, Vol 16, Num 17, pp 4339-4352, issn 1078-0432, 14 p.Article

JAK2^V617F : prevalence in a large Chinese hospital population. CommentaryPARDANANI, Animesh; XUESONG XU; QI ZHANG et al.Blood. 2007, Vol 109, Num 1, issn 0006-4971, 8,339-342 [5 p.]Article

Characterization of murine JAK2^V617F-positive myeloproliferative diseaseBUMM, Thomas G. P; ELSEA, Collin; CORBIN, Amie S et al.Cancer research (Baltimore). 2006, Vol 66, Num 23, pp 11156-11165, issn 0008-5472, 10 p.Article

JAK2 inhibitors: What's the true therapeutic potential?SANTOS, Fabio P. S; VERSTOVSEK, Srdan.Blood reviews. 2011, Vol 25, Num 2, pp 53-63, issn 0268-960X, 11 p.Article

Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria : PIH: Molecular mechanism, diagnosis, and treatment for myeloproliferative neoplasmsWADLEIGH, Martha; TEFFERI, Ayalew.International journal of hematology. 2010, Vol 91, Num 2, pp 174-179, issn 0925-5710, 6 p.Article

Intriguing outcome of JAK2V617F mutation seen in a patient with MYH9-related hereditary macrothrombocytopeniaFABRIS, Fabrizio; SCANDELLARI, Raffaella; VETTORE, Silvia et al.Thrombosis and haemostasis. 2010, Vol 104, Num 4, pp 858-859, issn 0340-6245, 2 p.Article

Myeloproliferative neoplasm induced by constitutive expression of JAK2^V617F in knock-in miceMARTY, Caroline; LACOUT, Catherine; MARTIN, Antoine et al.Blood. 2010, Vol 116, Num 5, pp 783-787, issn 0006-4971, 5 p.Article

Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1NILSSON, Jeanette; HELOU, Khalil; KOVACS, Anikó et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 5, pp 2020-2029, issn 0008-5472, 10 p.Article

JAK2 V617F and ringed sideroblasts : not necessarily RARS-TSTEENSMA, David P; TEFFERI, Ayalew.Blood. 2008, Vol 111, Num 3, pp 1748-1748, issn 0006-4971, 1 p.Article

On the molecular origins of the chronic myeloproliferative disorders : it all makes senseKAUSHANSKY, Kenneth.Blood. 2005, Vol 105, Num 11, pp 4187-4190, issn 0006-4971, 4 p.Article

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2^V617F-Driven DiseaseEVROT, Emeline; EBEL, Nicolas; HOFMANN, Francesco et al.Clinical cancer research (Print). 2013, Vol 19, Num 22, pp 6230-6241, issn 1078-0432, 12 p.Article

Janus Reveals Another Face: The Biologic Rationale for Targeting Janus Kinase 2 in LymphomaMULLALLY, Ann; EBERT, Benjamin L.Journal of clinical oncology. 2012, Vol 30, Num 33, pp 4168-4170, issn 0732-183X, 3 p.Article

A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasmsMINNUCCI, Giulia; AMICARELLI, Giulia; SALMOIRAGHI, Silvia et al.Haematologica (Roma). 2012, Vol 97, Num 9, pp 1394-1400, issn 0390-6078, 7 p.Article

JAK2-positive myeloproliferative neoplasm co-existing with systemic mastocytosisTHACHIL, Jecko; HAWKINS, Stephen; WOODCOCK, Barrie et al.British journal of haematology. 2011, Vol 152, Num 6, issn 0007-1048, p. 675Article

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphomaVAN ROOSBROECK, Katrien; COX, Luk; DE WOLF-PEETERS, Chris et al.Blood. 2011, Vol 117, Num 15, pp 4056-4064, issn 0006-4971, 9 p.Article

The JAK2 V617F somatic mutation, mortality and cancer risk in the general populationNIELSEN, Camilla; BIRGENS, Henrik S; NORDESTGAARD, Børge G et al.Haematologica (Roma). 2011, Vol 96, Num 3, pp 450-453, issn 0390-6078, 4 p.Article

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like diseaseAKADA, Hajime; DONGQING YAN; HAIYING ZOU et al.Blood. 2010, Vol 115, Num 17, pp 3589-3597, issn 0006-4971, 9 p.Article

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosisALCHALBY, Haefaa; BADBARAN, Anita; HILDEBRANDT, York et al.Blood. 2010, Vol 116, Num 18, pp 3572-3581, issn 0006-4971, 10 p.Article

Sex differences in the JAK2^V617F allele burden in chronic myeloproliferative disordersSTERN, Brady L; WILLIAMS, Donna M; WANG, Nae-Yuh et al.Haematologica (Roma). 2010, Vol 95, Num 7, pp 1090-1097, issn 0390-6078, 8 p.Article

Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in miceGORANTLA, Sivahari P; DECHOW, Tobias N; GRUNDLER, Rebekka et al.Blood. 2010, Vol 116, Num 22, pp 4600-4611, issn 0006-4971, 12 p.Article

Preferential nuclear accumulation of JAK2V617F in CD34⁺ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasiaRINALDI, Ciro R; RINAIDI, Paola; ALAGIA, Adele et al.Blood. 2010, Vol 116, Num 26, pp 6023-6026, issn 0006-4971, 4 p.Article

Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineageDA COSTA REIS MONTE-MOR, B; PLO, I; SAAD, S. T. O et al.Leukemia. 2009, Vol 23, Num 1, pp 144-152, issn 0887-6924, 9 p.Article

Mechanisms of Constitutive Activation of Janus Kinase 2-V617F Revealed at the Atomic Level Through Molecular Dynamics SimulationsLEE, Tai-Sung; WANLONG MA; XI ZHANG et al.Cancer. 2009, Vol 115, Num 8, pp 1692-1700, issn 0008-543X, 9 p.Article